Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial.
暂无分享,去创建一个
J. McKiernan | M. Benson | P. Gorroochurn | J. Capodice | A. Katz | A. Cammack | G. Eric | B. Stone | A. Cammack
[1] K. Iczkowski. Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. , 2009, Archives of pathology & laboratory medicine.
[2] F. Montorsi,et al. Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. , 2009, European urology.
[3] B. Tomlinson,et al. In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach? , 2008, Molecular nutrition & food research.
[4] M. Mori,et al. C‐reactive protein as a prognostic marker for men with androgen‐independent prostate cancer , 2008, Cancer.
[5] K. Tateda,et al. Oral administration of Bifidobacterium longum prevents gut‐derived Pseudomonas aeruginosa sepsis in mice , 2008, Journal of applied microbiology.
[6] T. Szekeres,et al. Novel resveratrol derivatives induce apoptosis and cause cell cycle arrest in prostate cancer cell lines. , 2007, Anticancer research.
[7] J. Mol,et al. Regulation of COX-2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation. , 2007, Journal of veterinary internal medicine.
[8] I. Thompson,et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. , 2007, The Journal of urology.
[9] Karla A. Lawson,et al. Supplemental and Dietary Vitamin E Intakes and Risk of Prostate Cancer in a Large Prospective Study , 2007, Cancer Epidemiology Biomarkers & Prevention.
[10] Amy Subar,et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. , 2007, Journal of the National Cancer Institute.
[11] B. Aggarwal,et al. Zyflamend, a Polyherbal Preparation, Inhibits Invasion, Suppresses Osteoclastogenesis, and Potentiates Apoptosis Through Down-Regulation of NF-κ B Activation and NF-κ B–Regulated Gene Products , 2007 .
[12] C. Franceschi,et al. Curcumin in Cell Death Processes: A Challenge for CAM of Age-Related Pathologies , 2007, Evidence-based complementary and alternative medicine : eCAM.
[13] Jianfeng Xu,et al. Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.
[14] A. Katz,et al. The Role of Zyflamend, an Herbal Anti-inflammatory, as a Potential Chemopreventive Agent Against Prostate Cancer: A Case Report , 2007, Integrative cancer therapies.
[15] R. Newman,et al. Zyflamend®-mediated inhibition of human prostate cancer PC3 cell proliferation: Effects on 12-LOX and Rb protein phosphorylation , 2006, Cancer biology & therapy.
[16] I. Thompson,et al. Defining high risk prostate cancer--where do we set the bar? A translational science approach to risk stratification. , 2006, The Journal of urology.
[17] D. Bostwick,et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. , 2006, The Journal of urology.
[18] J. Epstein,et al. Widespread High-grade Prostatic Intraepithelial Neoplasia on Prostatic Needle Biopsy: A Significant Likelihood of Subsequently Diagnosed Adenocarcinoma , 2006, The American journal of surgical pathology.
[19] E. Campo,et al. Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse , 2005, British Journal of Cancer.
[20] M. Mori,et al. Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies , 2005, Cancer.
[21] A. M. Snelling,et al. Effects of probiotics on the gastrointestinal tract , 2005, Current opinion in infectious diseases.
[22] M. Remzi,et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. , 2005, The Journal of urology.
[23] S. Shany,et al. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. , 2005, Anticancer research.
[24] Liang Cheng,et al. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens , 2005, Modern Pathology.
[25] R. Buttyan,et al. Zyflamend®, a Unique Herbal Preparation With Nonselective OX Inhibitory Activity, Induces Apoptosis of Prostate Cancer Cells That Lack COX-2 Expression , 2005, Nutrition and cancer.
[26] P. Humphrey,et al. High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population. , 2005, Urology.
[27] C. Cordon-Cardo,et al. Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism , 2005, Clinical Cancer Research.
[28] W. Isaacs,et al. The role of inflammation in the pathogenesis of prostate cancer. , 2004, The Journal of urology.
[29] Liang Cheng,et al. Nuclear Factor-κB Is Constitutively Activated in Prostate Cancer In vitro and Is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate , 2004, Clinical Cancer Research.
[30] R. Paterson,et al. Prostatic intraepithelial neoplasia: an update. , 2004, Clinical prostate cancer.
[31] H. Mukhtar,et al. Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells , 2003, Oncogene.
[32] M. Steiner,et al. Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. , 2003, Clinical prostate cancer.
[33] Yiwei Li,et al. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] H. Mukhtar,et al. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells , 2002, Oncogene.
[35] J. Epstein,et al. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? , 2001, The Journal of urology.
[36] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.
[37] K. Pienta,et al. Tumor Necrosis Factor-α-induced Apoptosis in Prostate Cancer Cells through Inhibition of Nuclear Factor-κB by an IκBα “Super-Repressor” , 2000 .
[38] M. Christian,et al. Phase I clinical trial design in cancer drug development. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] T. Wilt,et al. Epidemiology of High-Grade Prostatic Intraepithelial Neoplasia , 2000, Scandinavian journal of urology and nephrology. Supplementum.
[40] C. N. Coleman,et al. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen , 1999, Oncogene.
[41] D. Bostwick,et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. , 1995, The Journal of urology.
[42] D. Bostwick,et al. The pathology of early prostate cancer , 1989, CA: a cancer journal for clinicians.
[43] J. Epstein,et al. Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. , 2006, The Journal of urology.